References
- Nair AG, Asnani HT, Mehta VC, et al. Tyrosine kinase inhibitors in the treatment of choroidal metastases from non-small-cell lung cancer: A case report and review of literature. Ocul Oncol Pathol. 2017;3(1):28–33. doi:10.1159/000448114.
- Contreras-Diaz M, Medina-Tapia A, Martinez-Bernal G, et al. Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib. Arch Soc Esp Oftalmol. 2016;91(11):551–555. doi:10.1016/j.oftal.2016.03.002.
- Shah SU, Mashayekhi A, Shields CL, et al. Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients. Ophthalmology. 2014;121(1):352–357. doi:10.1016/j.ophtha.2013.07.014.
- Chen CJ, McCoy AN, Brahmer J, Handa JT. Emerging treatments for choroidal metastases. Surv Ophthalmol. 2011;56(6):511–521. doi:10.1016/j.survophthal.2011.05.001.
- Mariachiara M, Celeste R, Federico F, Nicole B, Antonio C. Choroidal metastasis from non-small-cell lung cancer responsive to osimertinib: a case report. Int Ophthalmol. 2018;38(6):2669–2675. doi:10.1007/s10792-017-0749-2.
- Dall’Olio FG, Ruatta C, Melotti B, Sperandi F, Ciardella AP, Ardizzoni A. Response to osimertinib in choroidal metastases from EGFRmt T790M-positive non-small cell lung adenocarcinoma. J Thorac Oncol. 2017;12(10): e165-e167. doi:10.1016/j.jtho.2016.09.002.
- Maskell D, Geropantas K, Kouroupis M, Glenn A, Ajithkumar T. Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs? Can J Ophthalmol. 2017;52(1):e22–25. doi:10.1016/j.jcjo.2016.09.010.
- Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology. 2016;17(5):577–589. doi:10.1016/S1470-2045(16)30033-X